A phase 1 trial of cue-101, a novel Hpv16 E7-Phla-Il2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic Hpv16+ head and neck cancer Meeting Abstract
| Authors: | Chung, C.; Colevas, A. D.; Gibson, M.; Adkins, D.; Sukari, A.; Wirth, L.; Burtness, B.; Bauman, J.; Rodriguez, C.; Worden, F.; Saba, N.; Glisson, B.; Dunn, L.; Seiwert, T.; Agensky, L.; Levisetti, M.; Lynam, R.; Margossian, S.; Moniz, R.; Quayle, S.; Pienta, K.; Pai, S. |
| Abstract Title: | A phase 1 trial of cue-101, a novel Hpv16 E7-Phla-Il2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic Hpv16+ head and neck cancer |
| Meeting Title: | 36th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2021) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 9 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Nov 10-14 |
| Meeting Location: | Washington, DC |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2021-11-01 |
| Start Page: | A468 |
| Language: | English |
| ACCESSION: | WOS:000774877500423 |
| DOI: | 10.1136/jitc-2021-SITC2021.438 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 438 -- Meeting was also presented virtually -- Source: Wos |
